Steven Pieper - 05 Mar 2026 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role: Chief Financial Officer
Signature: /s/ Beth Hecht, Attorney-in-Fact
Issuer symbol: XERS
Transactions as of: 05 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 05 Mar 2026, 19:18:28 UTC
Previous filing: 02 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Pieper Steven	Chief Financial Officer	C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO	/s/ Beth Hecht, Attorney-in-Fact	05 Mar 2026	0001875714

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XERS	Common Stock	Options Exercise		+27,891	+2%	$4.09^*	1,394,904	05 Mar 2026	Direct
transaction	XERS	Common Stock	Options Exercise		+14,036	+1%	$5.93^*	1,408,940	05 Mar 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XERS	Stock Option (Right to Buy)	Options Exercise		-27,891	-100%	$0.000000^*	0	05 Mar 2026	Common Stock	27,891	$4.09	Direct	F1
transaction	XERS	Stock Option (Right to Buy)	Options Exercise		-14,036	-100%	$0.000000^*	0	05 Mar 2026	Common Stock	14,036	$5.93	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person received the stock options on December 10, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan. 50% of the options vested on the first anniversary of the vesting commencement date, and the remaining 50% of options vested on the second anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.
F2	The reporting person received the stock options on January 31, 2018 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.

Content

The reporting person received the stock options on December 10, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan. 50% of the options vested on the first anniversary of the vesting commencement date, and the remaining 50% of options vested on the second anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.

The reporting person received the stock options on January 31, 2018 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.

Remarks:

Chief Financial Officer